Experimental drug aims to tame tough blood cancers
NCT ID NCT06563804
Summary
This study tested a new drug called S227928, both by itself and combined with an existing drug (venetoclax), for people with advanced forms of leukemia and related blood cancers that had stopped responding to standard treatments. The main goals were to find a safe and effective dose and to see if the treatment could help control the disease. The trial was terminated early after enrolling 13 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Bordeaux - Hopital du Haut Levêque
Pessac, 33604, France
-
Chu de Nice - Hôpital L'archet 1
Nice, 062000, France
-
City of Hope
Duarte, California, 91010, United States
-
Fred Hutch Cancer Center
Seattle, Washington, 98109, United States
-
Helsinki University Hospital - Comprehensive Cancer Center
Helsinki, 00029, Finland
-
Institut Gustave Roussy
Villejuif, 94800, France
-
Institut Paoli Calmette
Marseille, 13009, France
-
Klinikum rechts der Isar der TU München
München, 81675, Germany
-
Memorial Sloan Kettering
New York, New York, 10065, United States
-
Peter MacCallum Cancer Centre
Melbourne, 3000, Australia
-
Prince of Wales Hospital
Randwick, 2031, Australia
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sapporo Hokuyu Hospital
Hokkaido, 003-0006, Japan
-
The University of Kansas
Fairway, Kansas, 66205, United States
-
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Tokyo, 113-8677, Japan
-
Universitätsklinikum Ulm
Ulm, 89081, Germany
Conditions
Explore the condition pages connected to this study.